HAEMONETICS CORP

Haemonetics maintains a debt-to-equity ratio of 1.34 and a current ratio of 1.75, indicating moderate leverage and adequate short-term liquidity. The company's liquidity position is supported by $363.4 million in cash and equivalents, though net cash is negative after subtracting total debt, signaling potential liquidity risk. Free cash flow of $207.2 million in the latest quarter reflects strong operational cash generation, though capital expenditures of $15.1 million suggest ongoing investment in infrastructure. Profitability metrics show a return on equity of 12.89% and a return on assets of 4.72%, both below the industry median for medical equipment firms. Gross margin of 59.6% (Q3 2026) is stable compared to 55.6% in the same period last year, but operating margin of 18.2% is down from 17.4% in 2024, reflecting higher R&D and SG&A expenses. The company's operating income of $179.8 million in Q3 2026 is 19.3% higher than the same period in 2024, but this growth is partially offset by increased interest expenses and amortization costs. Geographically, Haemonetics derives 62% of revenue from North America, with 28% from Europe and 10% from other regions. Segment-wise, the Plasma segment contributes 45% of total revenue, followed by Hospital (35%) and Blood Center (20%). This concentration in North America and the Plasma segment exposes the company to regional regulatory and demand risks. Revenue growth has slowed to 3.7% year-to-date (Q3 2026 vs. Q3 2024), down from 5.2% in the prior quarter. Outlook for FY2026 projects a 4.0% revenue increase, driven by plasma collection demand and hospital product adoption, but FY2027 guidance is tempered by potential supply chain disruptions and competitive pricing pressures. The company's R&D spending of $45.3 million in nine months ended December 2025 reflects ongoing innovation in blood management technologies. Risk factors include medium dilution potential due to $75 million in recent share repurchases and $185.5 million in convertible note redemptions, with adjustments applied to custom valuations for equity dilution risk. The company's liquidity risk is elevated by $1.2 billion in total debt, though cash flow generation and asset liquidity mitigate this to a medium rating. Regulatory risks are moderate, with no material geopolitical drivers identified in the industry configuration. Recent filings highlight a $12.6 million gain on convertible note repurchases and $9.3 million in intangible asset impairments, signaling capital structure management and asset rationalization efforts. The company's cash flows from financing activities were negative $76.96 million in nine months ended December 2025, driven by debt repayments and share repurchases.